UBS Warburg is set to lead-manage the largest ever initial public offering on the Neuer Markt for a biotechnology company when it launches the IPO for Genmab next month.
The Genmab IPO takes biotech issues in Europe since July past the €1bn ($880m) mark, reinforcing the strength of the sector and investors' insatiable appetite for the high-quality paper.